VIP and pulmonary arterial hypertension: Previous studies using other compounds to treat pulmonary hypertension in the monocrotaline model including statins, endothelin blockade, rapamycin and vasoactive intestinal peptide have shown that the timing of initiation of therapy is crucial [13], [14], [16], [18], [19].